# CYP2A7

## Overview
CYP2A7 is a gene that encodes the cytochrome P450 family 2 subfamily A member 7 protein, which is part of the cytochrome P450 superfamily of enzymes. These enzymes are primarily involved in the metabolism of various endogenous and exogenous compounds, including drugs and xenobiotics. Although CYP2A7 shares structural similarities with other members of the CYP2A subfamily, such as CYP2A6, it is catalytically inactive due to its inability to effectively bind heme, a critical component for enzymatic activity (Lewis1999Molecular). Despite this, CYP2A7 has been shown to participate in the hydroxylation of certain substrates, such as diclofenac, indicating a role in drug metabolism (Ashraf2024Identification). Additionally, CYP2A7 mRNA can interact with microRNAs, influencing the expression of other cytochrome P450 enzymes, thereby playing a regulatory role in gene expression (Nakano2015CYP2A7). Emerging research suggests potential implications of CYP2A7 in colorectal cancer, highlighting its significance in both pharmacology and disease pathology (Thean2017Chromosome).

## Structure
The human cytochrome P450 2A7 (CYP2A7) protein is part of the CYP2A subfamily, which is involved in the metabolism of xenobiotics. The primary structure of CYP2A7 consists of 494 amino acids (Lodhi2015In). The secondary structure is predominantly alpha-helical, comprising 14 alpha helices and 6 beta strands (Lodhi2015In). The tertiary structure of CYP2A7 was modeled using homology modeling with the 2FDV chain A as a template, which shares a 94% sequence identity with CYP2A7. This model was validated with tools like PROCHECK and VERIFY3D, indicating a high-quality structure with 94.8% of residues in the most favored regions of the Ramachandran plot (Lodhi2015In).

CYP2A7 is noted for its structural similarity to CYP2A6, but it is catalytically inactive due to its inability to effectively bind heme, attributed to the replacement of Arg128 with leucine (Lewis1999Molecular). The protein's active sites were predicted using computational tools, identifying potential binding sites and cavity-lining residues (Lodhi2015In). The quaternary structure of CYP2A7 is not detailed in the available literature. The protein's structural analysis provides insights into its potential role in cancer cells and the possibility of targeting it with inhibitors (Lodhi2015In).

## Function
CYP2A7 is a member of the cytochrome P450 superfamily, which is involved in the metabolism of various substances within the body. Although CYP2A7 is relatively understudied compared to other P450 enzymes, it is known to participate in the hydroxylation of certain substrates. Specifically, CYP2A7 can metabolize diclofenac, a common nonsteroidal anti-inflammatory drug, producing hydroxydiclofenac, indicating its role as a drug-metabolizing enzyme (Ashraf2024Identification). However, CYP2A7 does not metabolize standard CYP2A6 substrates such as nicotine, coumarin, or 7-ethoxycoumarin, suggesting distinct substrate specificity compared to CYP2A6 (Ashraf2024Identification).

CYP2A7 also exhibits significant futile cycling activity, which involves the reduction of electron transfer partners in the absence of substrate, leading to the production of superoxide anions (Ashraf2024Identification). This activity may have implications for oxidative stress within cells. Additionally, CYP2A7 mRNA can act as a decoy for miR-126*, a microRNA that downregulates CYP2A6 expression, thereby influencing the expression of CYP2A6 in human liver cells (Nakano2015CYP2A7). This regulatory mechanism highlights the potential role of CYP2A7 in modulating gene expression through microRNA interactions.

## Clinical Significance
The clinical significance of the CYP2A7 gene is not as well-documented as other members of the cytochrome P450 family, but emerging research suggests potential implications in colorectal cancer. A study identified a genomic deletion at chromosome 19q13, which includes the CYP2A7 gene, in familial colorectal cancer patients who are negative for APC mutations. This deletion was associated with significantly reduced expression of CYP2A7 in polyps compared to matched mucosa, suggesting a possible role in colorectal tumorigenesis (Thean2017Chromosome). The deletion may disrupt regulatory elements, affecting the expression of neighboring genes involved in tumorigenic processes, such as TGFβ1, MIA, and RAB4B (Thean2017Chromosome).

While the specific role of CYP2A7 in drug metabolism is not fully understood, it has been shown to hydroxylate diclofenac, indicating its potential involvement in drug metabolism (Ashraf2024Identification). The enzyme's inhibition by compounds like ketoconazole suggests that alterations in CYP2A7 activity could lead to drug-drug interactions (Ashraf2024Identification). However, the clinical implications of these interactions remain to be fully elucidated. Further research is needed to clarify the role of CYP2A7 in disease susceptibility and drug metabolism.


## References


[1. (Lodhi2015In) Sharad S. Lodhi, Rohit Farmer, Yogesh K. Jaiswal, and Gulshan Wadhwa. In silico structural, virtual screening and docking studies of human cytochrome p450 2a7 protein. Interdisciplinary Sciences: Computational Life Sciences, 7(2):129–135, June 2015. URL: http://dx.doi.org/10.1007/s12539-015-0007-0, doi:10.1007/s12539-015-0007-0. This article has 3 citations.](https://doi.org/10.1007/s12539-015-0007-0)

[2. (Nakano2015CYP2A7) Masataka Nakano, Yasunari Fukushima, Shin-ichi Yokota, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, Tsuyoshi Yokoi, and Miki Nakajima. Cyp2a7 pseudogene transcript affects cyp2a6 expression in human liver by acting as a decoy for mir-126*. Drug Metabolism and Disposition, 43(5):703–712, February 2015. URL: http://dx.doi.org/10.1124/dmd.115.063255, doi:10.1124/dmd.115.063255. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/dmd.115.063255)

[3. (Thean2017Chromosome) Lai Fun Thean, Yu Hui Wong, Michelle Lo, Carol Loi, Min Hoe Chew, Choong Leong Tang, and Peh Yean Cheah. Chromosome 19q13 disruption alters expressions of cyp2a7, mia and mia-rab4b lncrna and contributes to fap-like phenotype in apc mutation-negative familial colorectal cancer patients. PLOS ONE, 12(3):e0173772, March 2017. URL: http://dx.doi.org/10.1371/journal.pone.0173772, doi:10.1371/journal.pone.0173772. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0173772)

[4. (Ashraf2024Identification) Rana Azeem Ashraf, Sijie Liu, Clemens Alexander Wolf, Gerhard Wolber, and Matthias Bureik. Identification of new substrates and inhibitors of human cyp2a7. Molecules, 29(10):2191, May 2024. URL: http://dx.doi.org/10.3390/molecules29102191, doi:10.3390/molecules29102191. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/molecules29102191)

[5. (Lewis1999Molecular) D.F.V Lewis, M Dickins, B.G Lake, P.J Eddershaw, M.H Tarbit, and P.S Goldfarb. Molecular modelling of the human cytochrome p450 isoform cyp2a6 and investigations of cyp2a substrate selectivity. Toxicology, 133(1):1–33, March 1999. URL: http://dx.doi.org/10.1016/s0300-483x(98)00149-8, doi:10.1016/s0300-483x(98)00149-8. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0300-483x(98)00149-8)